09939 開拓藥業－Ｂ
按盘价 
1.220 -0.020 (-1.613%) 盈利能力分析
| 2024/12 | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| 资产回报率 (%) | -22.435% | -72.550% | -46.293% | -42.970% | -42.273% |
| 股东资金回报率 (%) | -41.291% | -108.618% | -60.588% | -53.245% | -54.144% |
| 资本运用回报率 (%) | -44.567% | -164.595% | -54.943% | -45.562% | -30.217% |
边际利润分析
| 2024/12 | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| 毛利率 (%) | -94.600% | N/A | N/A | -- | N/A |
| 未计利息、税项、折旧及摊销前利润率 (%) | -2623.000% | N/A | N/A | -2457.246% | N/A |
| 税前边际利润率 (%) | -3105.480% | N/A | N/A | -2460.036% | N/A |
| 纯利率 (%) | -3105.840% | N/A | N/A | -2460.036% | N/A |
变现能力分析
| 2024/12 | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| 流动比率 (X) | 1.030 X | 2.103 X | 4.740 X | 6.944 X | 8.389 X |
| 速动比率 (X) | 1.017 X | 2.103 X | 2.843 X | 5.345 X | 8.389 X |
财务杠杆分析
| 2024/12 | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| 总负债 / 总资产比率 (%) | 42.911% | 47.297% | 27.246% | 19.963% | 18.555% |
| 总债项 / 总资产比率 (%) | 25.821% | 29.212% | 13.935% | 7.724% | 11.974% |
| 净债项 / 总资产比率 (%) | -2.797% | -22.040% | -28.158% | -37.254% | -45.579% |
| 总债项 / 股东资金比率 (%) | 45.229% | 55.427% | 19.154% | 9.651% | 14.702% |
| 长期债项 / 股东资金比率 (%) | 6.801% | 29.619% | 12.243% | 9.079% | 8.979% |
| 净债项 / 股东资金比率 (%) | -4.900% | -41.819% | -38.704% | -46.546% | -55.963% |
| 净现金 / (债项) ($) | 1.44千万 | 1.92亿 | 5.79亿 | 7.70亿 | 8.44亿 |
| 每股净现金 / (债项) ($) | 0.032 | 0.428 | 1.293 | 1.988 | 2.285 |
| 总债项 / 资本运用比率 (%) | 38.172% | 39.398% | 16.487% | 8.642% | 13.180% |
| 利息盈利率 (X) | N/A | N/A | N/A | N/A | N/A |
营运效率分析
| 2024/12 | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| 存货周转率日数 (日) | 83.091日 | N/A | -- | -- | N/A |
| 应收贸易帐周转率日数 (日) | N/A | N/A | N/A | N/A | N/A |
| 应付贸易帐周转率日数 (日) | 4473.331日 | N/A | N/A | 1075.706日 | N/A |
| 备注： | 实时报价更新时间为16/05/2025 17:59 |
| 港股实时基本市场行情由香港交易所提供; 香港交易所指定免费发放实时基本市场行情的网站。 | |
| 股东应占溢利/(亏损) () | RMB -155,292,000 |
| 增长率 | -85.361% |
| 每股盈利/(亏损) | RMB -0.360 |
| 每股账面资产净值 (¥) | RMB 0.657 |